OMER

$0.00

(

0.00%

)
Quote details

stock

Omeros Corporation

NASDAQ | OMER

10.08

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$709.14M

Market Cap

-

P/E Ratio

-2.36

EPS

$13.60

52 Week High

$2.95

52 Week Low

HEALTHCARE

Sector

OMER Chart

Recent Chart
Price Action

OMER Technicals

Tags:

OMER Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$950K
Total Revenue $0
Cost Of Revenue $950K
Costof Goods And Services Sold $950K
Operating Income -$169M
Selling General And Administrative $50M
Research And Development $120M
Operating Expenses $169M
Investment Income Net -
Net Interest Income -$13M
Interest Income $11M
Interest Expense $25M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $950K
Income Before Tax -$157M
Income Tax Expense $26M
Interest And Debt Expense -
Net Income From Continuing Operations -$183M
Comprehensive Income Net Of Tax -
Ebit -$158M
Ebitda -$157M
Net Income -$157M

Revenue & Profitability

Earnings Performance

OMER Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $277M
Total Current Assets $134M
Cash And Cash Equivalents At Carrying Value $3.4M
Cash And Short Term Investments $3.4M
Inventory -
Current Net Receivables $37M
Total Non Current Assets $143M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $87M
Other Current Assets $7.2M
Other Non Current Assets -
Total Liabilities $460M
Total Current Liabilities $80M
Current Accounts Payable $5.9M
Deferred Revenue -
Current Debt -
Short Term Debt $27M
Total Non Current Liabilities $380M
Capital Lease Obligations $19M
Long Term Debt $167M
Current Long Term Debt $21M
Long Term Debt Noncurrent -
Short Long Term Debt Total $207M
Other Current Liabilities $47M
Other Non Current Liabilities $196M
Total Shareholder Equity -$183M
Treasury Stock -
Retained Earnings -$910M
Common Stock $580K
Common Stock Shares Outstanding $58M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$149M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $950K
Capital Expenditures $165K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $82M
Cashflow From Financing $63M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$12M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$157M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$950K
Total Revenue $0
Cost Of Revenue $950K
Costof Goods And Services Sold $950K
Operating Income -$169M
Selling General And Administrative $50M
Research And Development $120M
Operating Expenses $169M
Investment Income Net -
Net Interest Income -$13M
Interest Income $11M
Interest Expense $25M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $950K
Income Before Tax -$157M
Income Tax Expense $26M
Interest And Debt Expense -
Net Income From Continuing Operations -$183M
Comprehensive Income Net Of Tax -
Ebit -$158M
Ebitda -$157M
Net Income -$157M

OMER News

OMER Profile

Omeros Corporation Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Omeros Corporation is a Seattle-based biopharmaceutical firm that specializes in the discovery, development, and commercialization of novel therapeutics aimed at serious conditions. The company boasts a diverse pipeline featuring both protein and small molecule therapies, targeting critical unmet medical needs in areas such as inflammation, complement-mediated diseases, and central nervous system (CNS) disorders. With a strategic focus on orphan indications, Omeros is well-equipped to drive growth and make significant advancements in patient care, positioning itself as a leader in innovative treatment solutions.

VHAI
-20.00%
$0.00
VIVK
+1.62%
$0.29
YYAI
-6.47%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
BITF
-15.68%
$5.45
RXRX
-6.33%
$6.36
PLUG
-7.01%
$3.58
ADAP
+15.31%
$0.21
YDKG
-55.45%
$0.08
NVTS
+4.35%
$15.82
BYND
-14.17%
$0.67
RGTI
-12.76%
$49.15
DNN
-1.57%
$3.12
IVF
+72.41%
$1.30
NIO
-1.02%
$6.75
MIRA
+29.16%
$1.70
SCNX
+0.26%
$0.71
WHWK
+21.80%
$2.55
F
-0.63%
$11.68
BBD
+1.40%
$3.24
ACHR
-8.12%
$11.97
AXDX
-61.36%
$0.03
TLRY
-8.92%
$1.53
INTC
-1.10%
$36.74
IONZ
+15.58%
$3.32
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
CAN
-15.31%
$1.65
DFLI
-31.72%
$1.34
ETHD
+4.23%
$3.94
TSLA
-2.45%
$424.45
GDXD
-8.97%
$0.60
LAES
-15.15%
$6.35
VSEE
-8.84%
$0.54
AMD
-1.30%
$235.49
MARA
-10.98%
$20.32
GNPX
-47.58%
$0.44
RIG
-3.32%
$3.20
LGCB
+35.15%
$2.23
SOFI
-5.08%
$26.60
BTG
+3.03%
$5.84
CLF
-3.13%
$13.51
ABAT
-36.42%
$5.69
AAL
-5.76%
$11.78
KVUE
-10.83%
$14.49
CLSK
+5.55%
$23.20
NAK
-16.47%
$2.20
QBTS
-9.51%
$40.51
QSI
-2.66%
$2.56
RGTZ
+28.73%
$11.19
MASK
+16.15%
$0.56
RR
-6.38%
$5.76
BTBT
-8.25%
$3.72
CIFR
-10.08%
$18.91
UUUU
-11.06%
$22.22
FEMY
+31.43%
$0.72
QS
-12.16%
$15.67
CRML
-10.62%
$20.30
RMBL
+60.50%
$3.21
IREN
-8.20%
$62.40
GPUS
-6.53%
$0.36
QUBT
-10.73%
$18.95
ADD
-25.47%
$0.05
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
SNAP
-3.53%
$7.63
RF
-4.89%
$23.53
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
PLTR
-0.81%
$178.16
SMR
-7.73%
$49.29
SOUN
-3.59%
$20.63
KDLY
+1.29%
$0.79
ASST
-11.43%
$0.85
MU
+4.78%
$201.11
APLD
-1.46%
$37.20
TOVX
-44.55%
$0.46
SLNH
+1.86%
$4.37
NOK
+0.44%
$5.67
WTO
-88.54%
$0.13
HBAN
-4.62%
$15.46
WULF
-8.82%
$14.10
SATL
-27.65%
$2.99
AMC
-1.77%
$2.77
ELWS
+48.09%
$5.45
SOND
+60.86%
$1.48
HIMS
-6.93%
$58.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
PFE
-0.12%
$24.35
KEY
-6.45%
$16.58
JBLU
-5.73%
$4.66
CRWV
+1.57%
$141.43
WLGS
-5.57%
$0.04
BAC
-2.83%
$50.80
AAPL
-1.06%
$246.68
GRAB
-3.23%
$5.72
VHAI
-20.00%
$0.00
VIVK
+1.62%
$0.29
YYAI
-6.47%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
BITF
-15.68%
$5.45
RXRX
-6.33%
$6.36
PLUG
-7.01%
$3.58
ADAP
+15.31%
$0.21
YDKG
-55.45%
$0.08
NVTS
+4.35%
$15.82
BYND
-14.17%
$0.67
RGTI
-12.76%
$49.15
DNN
-1.57%
$3.12
IVF
+72.41%
$1.30
NIO
-1.02%
$6.75
MIRA
+29.16%
$1.70
SCNX
+0.26%
$0.71
WHWK
+21.80%
$2.55
F
-0.63%
$11.68
BBD
+1.40%
$3.24
ACHR
-8.12%
$11.97
AXDX
-61.36%
$0.03
TLRY
-8.92%
$1.53
INTC
-1.10%
$36.74
IONZ
+15.58%
$3.32
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
CAN
-15.31%
$1.65
DFLI
-31.72%
$1.34
ETHD
+4.23%
$3.94
TSLA
-2.45%
$424.45
GDXD
-8.97%
$0.60
LAES
-15.15%
$6.35
VSEE
-8.84%
$0.54
AMD
-1.30%
$235.49
MARA
-10.98%
$20.32
GNPX
-47.58%
$0.44
RIG
-3.32%
$3.20
LGCB
+35.15%
$2.23
SOFI
-5.08%
$26.60
BTG
+3.03%
$5.84
CLF
-3.13%
$13.51
ABAT
-36.42%
$5.69
AAL
-5.76%
$11.78
KVUE
-10.83%
$14.49
CLSK
+5.55%
$23.20
NAK
-16.47%
$2.20
QBTS
-9.51%
$40.51
QSI
-2.66%
$2.56
RGTZ
+28.73%
$11.19
MASK
+16.15%
$0.56
RR
-6.38%
$5.76
BTBT
-8.25%
$3.72
CIFR
-10.08%
$18.91
UUUU
-11.06%
$22.22
FEMY
+31.43%
$0.72
QS
-12.16%
$15.67
CRML
-10.62%
$20.30
RMBL
+60.50%
$3.21
IREN
-8.20%
$62.40
GPUS
-6.53%
$0.36
QUBT
-10.73%
$18.95
ADD
-25.47%
$0.05
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
SNAP
-3.53%
$7.63
RF
-4.89%
$23.53
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
PLTR
-0.81%
$178.16
SMR
-7.73%
$49.29
SOUN
-3.59%
$20.63
KDLY
+1.29%
$0.79
ASST
-11.43%
$0.85
MU
+4.78%
$201.11
APLD
-1.46%
$37.20
TOVX
-44.55%
$0.46
SLNH
+1.86%
$4.37
NOK
+0.44%
$5.67
WTO
-88.54%
$0.13
HBAN
-4.62%
$15.46
WULF
-8.82%
$14.10
SATL
-27.65%
$2.99
AMC
-1.77%
$2.77
ELWS
+48.09%
$5.45
SOND
+60.86%
$1.48
HIMS
-6.93%
$58.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
PFE
-0.12%
$24.35
KEY
-6.45%
$16.58
JBLU
-5.73%
$4.66
CRWV
+1.57%
$141.43
WLGS
-5.57%
$0.04
BAC
-2.83%
$50.80
AAPL
-1.06%
$246.68
GRAB
-3.23%
$5.72

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.